GO:0001937 negative regulation of endothelial cell proliferation: Signaling Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001937 describes any biological process that stops, prevents, or reduces the rate or extent of endothelial cell proliferation, a key control point in angiogenesis.
• Negative regulation of endothelial cell proliferation is essential for vascular homeostasis and is disrupted in cancer, atherosclerosis, and other angiogenesis-dependent diseases.
• Key molecular players include Notch1 signaling, KLF15/VASN, EPAS1, GNAI2, and microRNAs that suppress endothelial cell cycle progression.
• Endothelial cell proliferation is also regulated by non-coding RNAs and RNA modifications, such as piR-31115 and METTL3-mediated m6A modification of YAP1.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal testing of candidate negative regulators in endothelial cells.
• Understanding this process informs anti-angiogenic therapy, vascular normalization strategies, and tissue regeneration research.
Description
Endothelial cells line the inner surface of blood vessels and their proliferation is a fundamental step in angiogenesis, the formation of new blood vessels from pre-existing ones. The Gene Ontology term GO:0001937, negative regulation of endothelial cell proliferation, encompasses any process that stops, prevents, or reduces the rate or extent of endothelial cell proliferation. This regulatory process is critical for maintaining vascular quiescence in healthy tissues and for preventing excessive or aberrant angiogenesis in disease. Dysregulated endothelial cell proliferation contributes to tumor progression, atherosclerosis, and other pathological conditions, making its negative regulators attractive therapeutic targets. Recent studies have identified diverse molecular mechanisms, including Notch1 signaling, G protein subunit alpha i2, and microRNAs, that suppress endothelial cell proliferation. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a research-grade overview of GO:0001937, its key genes, disease relevance, and experimental approaches for studying it.
negative regulation of endothelial cell proliferation At A Glance
| GO ID | GO:0001937 |
|---|---|
| GO term | negative regulation of endothelial cell proliferation |
| Ontology | biological_process |
| Synonym | down regulation of endothelial cell proliferation, down-regulation of endothelial cell proliferation, downregulation of endothelial cell proliferation, inhibition of endothelial cell proliferation |
| Major function | Stops, prevents, or reduces the rate or extent of endothelial cell proliferation |
| Related process | Angiogenesis, vascular homeostasis |
| Key regulators | Notch1, KLF15/VASN, EPAS1, GNAI2, microRNAs, piR-31115 |
| Disease relevance | Cancer, atherosclerosis, angiogenesis-dependent disorders |
What Is GO:0001937?
GO:0001937, negative regulation of endothelial cell proliferation, is defined as any process that stops, prevents, or reduces the rate or extent of endothelial cell proliferation. In other words, it covers the biological mechanisms that put the brakes on the division of endothelial cells, which form the lining of blood vessels. This regulation is essential for controlling angiogenesis and maintaining vascular homeostasis.
Why Is negative regulation of endothelial cell proliferation Important in Cell Biology?
Negative regulation of endothelial cell proliferation is a central control point in angiogenesis and vascular biology. It ensures that blood vessel growth is tightly controlled, preventing excessive proliferation that can fuel tumor growth or contribute to vascular diseases such as atherosclerosis. Understanding the molecular mechanisms that inhibit endothelial cell proliferation can reveal new therapeutic targets for anti-angiogenic therapy and for promoting vascular normalization.
• Maintains vascular quiescence and prevents aberrant angiogenesis.
• Dysregulation is implicated in tumor progression and metastasis.
• Plays a role in atherosclerosis initiation at disturbed flow sites.
• Involved in skeletal muscle capillary-to-fiber ratio regulation.
• Modulated by non-coding RNAs and RNA modifications.
• Key for developing anti-angiogenic therapies.
• Relevant to tissue regeneration and wound healing.
• Provides targets for CRISPR-based functional genomics.
• Helps understand endothelial heterogeneity across vascular beds.
• Informs strategies for vascular normalization in cancer.
What Happens During negative regulation of endothelial cell proliferation?
Initiation by extracellular cues
In simple terms: Signals from outside the cell tell endothelial cells to stop dividing.
Negative regulation of endothelial cell proliferation often begins with extracellular cues such as Notch ligands, VEGF gradients, or shear stress. For example, Notch1 signaling activated by KLF15/VASN axis inhibits angiogenesis by suppressing endothelial cell proliferation. Similarly, disturbed flow can induce EPAS1, which attenuates atherosclerosis initiation by modulating endothelial fatty acid uptake and proliferation.
Receptor-mediated signaling
In simple terms: Receptors on the cell surface relay the stop signal into the cell.
Receptor-mediated signaling pathways, including Notch and G protein-coupled receptor pathways, transmit inhibitory signals. G protein subunit alpha i2 (GNAI2) plays a pivotal role in angiogenesis by negatively regulating endothelial cell proliferation. VEGF and Notch signaling coordinate endothelial cell differentiation and arterial specification, with Notch acting as a negative regulator of proliferation.
Intracellular signal transduction
In simple terms: Inside the cell, a cascade of molecules passes the message to the nucleus.
Intracellular kinases and phosphatases transduce the inhibitory signal. For instance, the KLF15/VASN axis activates Notch1 signaling, which then suppresses pro-proliferative genes. MicroRNAs can also negatively regulate angiogenesis by targeting mRNAs involved in endothelial cell proliferation.
Gene expression changes
In simple terms: The cell changes which genes are turned on or off to stop division.
Transcriptional and post-transcriptional changes underlie the inhibition of proliferation. EPAS1 (HIF-2α) modulates gene expression in response to flow, affecting endothelial cell proliferation. Additionally, piR-31115 from triple-negative breast cancer cells promotes endothelial cell proliferation via METTL3-mediated m6A modification of YAP1, indicating that RNA modifications can regulate this process.
Cell cycle arrest and functional outcome
In simple terms: The cell cycle stops, and endothelial cells remain quiescent.
Ultimately, negative regulation leads to cell cycle arrest, reduced DNA synthesis, and maintenance of endothelial quiescence. This prevents excessive vessel growth and is essential for vascular homeostasis. In skeletal muscle, RAB3GAP2 regulates endothelial cell proliferation and capillary-to-fiber ratio, highlighting tissue-specific control.
Key Genes Involved in GO:0001937 negative regulation of endothelial cell proliferation
The following genes and proteins have been experimentally implicated in the negative regulation of endothelial cell proliferation, based on verified PubMed literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| KLF15 | Activates Notch1 signaling to inhibit angiogenesis | Endothelial KLF15/VASN axis suppresses proliferation |
| VASN | Part of KLF15/VASN axis activating Notch1 | Inhibits angiogenesis via Notch1 |
| NOTCH1 | Receptor that negatively regulates endothelial proliferation | Key mediator of inhibitory signaling |
| EPAS1 | Attenuates atherosclerosis initiation at disturbed flow sites | Modulates endothelial fatty acid uptake and proliferation |
| GNAI2 | G protein subunit alpha i2; pivotal role in angiogenesis | Negatively regulates endothelial cell proliferation |
| RAB3GAP2 | Regulator of skeletal muscle endothelial cell proliferation | Associated with capillary-to-fiber ratio |
| YAP1 | Effector of proliferation; modified by m6A | Target of piR-31115/METTL3 axis |
| METTL3 | m6A methyltransferase | Mediates m6A modification of YAP1 |
| MIRNAs | Negative regulators of angiogenesis | Suppress endothelial cell proliferation |
| VEGFA | Pro-angiogenic factor; context-dependent | Interplay with Notch signaling |
| DLL4 | Notch ligand | Regulates endothelial proliferation |
| HEY1 | Notch target gene | Downstream effector of Notch signaling |
| HES1 | Notch target gene | Downstream effector of Notch signaling |
| CDKN1A | Cell cycle inhibitor p21 | Potential mediator of proliferation arrest |
| CDKN1B | Cell cycle inhibitor p27 | Potential mediator of proliferation arrest |
| TP53 | Tumor suppressor | Can induce cell cycle arrest in endothelial cells |
| PTEN | Phosphatase and tensin homolog | Negative regulator of PI3K/AKT pathway |
| SPRY2 | Sprouty RTK signaling antagonist | Inhibits angiogenic signaling |
How Is negative regulation of endothelial cell proliferation Regulated?
Negative regulation of endothelial cell proliferation is itself controlled by multiple layers of regulation. Notch1 signaling, activated by KLF15/VASN, directly suppresses pro-proliferative gene expression. GNAI2 modulates angiogenic signaling through G protein-coupled pathways. MicroRNAs provide post-transcriptional regulation by targeting mRNAs encoding proliferation-promoting factors. Additionally, RNA modifications such as m6A can influence the stability and translation of transcripts like YAP1, thereby affecting endothelial proliferation. Hemodynamic forces, such as disturbed flow, regulate EPAS1 expression and downstream fatty acid uptake, which in turn affects endothelial proliferation and atherosclerosis initiation.
negative regulation of endothelial cell proliferation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| YAP1 | Triple-negative breast cancer angiogenesis | Knockout or overexpression in endothelial cells |
| EPAS1 | Atherosclerosis initiation | Point mutation or knockout in mouse models |
| GNAI2 | Angiogenesis-related disorders | Knockout in zebrafish or mouse |
| RAB3GAP2 | Skeletal muscle capillary deficiency | Knockout in muscle endothelial cells |
| NOTCH1 | Vascular anomalies and cancer | Knock-in of activating mutations |
Cancer and tumor angiogenesis
Negative regulation of endothelial cell proliferation is often bypassed in tumors to support angiogenesis. For example, triple-negative breast cancer cell-derived piR-31115 promotes endothelial cell proliferation and migration via METTL3-mediated m6A modification of YAP1, highlighting a mechanism by which tumors overcome inhibitory signals. MicroRNAs that negatively regulate angiogenesis are frequently downregulated in cancers, leading to increased endothelial proliferation.
Atherosclerosis
EPAS1 attenuates atherosclerosis initiation at disturbed flow sites by modulating endothelial fatty acid uptake and proliferation. Loss of negative regulation at these sites can lead to endothelial dysfunction and plaque formation. This links GO:0001937 directly to cardiovascular disease pathogenesis.
Skeletal muscle vascularization
RAB3GAP2 regulates skeletal muscle endothelial cell proliferation and is associated with capillary-to-fiber ratio. Dysregulation of this process may contribute to muscle vascular insufficiency and metabolic disorders. This underscores the tissue-specific roles of negative regulators.
From negative regulation of endothelial cell proliferation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate endothelial proliferation? | CRISPR knockout in HUVECs or mouse endothelial cells |
| Does a specific point mutation alter inhibitory function? | Point mutation knock-in via CRISPR |
| Does overexpression of gene X suppress proliferation? | Lentiviral overexpression in endothelial cells |
| Does tagged gene X localize to specific compartments? | Tagged knock-in (e.g., GFP) |
| Does gene X regulate capillary-to-fiber ratio in vivo? | Endothelial-specific knockout mouse |
| Does non-coding RNA X affect endothelial proliferation? | Overexpression or knockout of ncRNA |
How to Study the negative regulation of endothelial cell proliferation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Loss-of-function effects on proliferation | Identify negative regulators |
| RNA-seq | Transcriptional changes | Profile gene expression after perturbation |
| m6A-seq | RNA methylation sites | Study epitranscriptomic regulation |
| EdU incorporation | DNA synthesis | Quantify proliferation |
| Ki-67 staining | Proliferation marker | Assess cell cycle entry |
| Matrigel plug assay | In vivo angiogenesis | Test negative regulators in vivo |
| Retinal angiogenesis model | Vascular sprouting | Study developmental angiogenesis |
| Tumor xenograft | Tumor angiogenesis | Evaluate anti-angiogenic targets |
CRISPR screening for negative regulators
Genome-wide CRISPR knockout or activation screens in endothelial cells can identify genes whose loss or gain alters proliferation. Such screens have uncovered regulators like GNAI2 and Notch pathway components. Libraries targeting kinases, phosphatases, or non-coding RNAs can be customized.
Transcriptomic and epitranscriptomic profiling
RNA-seq and m6A-seq can reveal changes in gene expression and RNA modifications upon modulation of negative regulators. For example, METTL3-mediated m6A modification of YAP1 was identified using such approaches. MicroRNA profiling can identify negative regulators of angiogenesis.
Functional proliferation assays
EdU incorporation, Ki-67 staining, and cell counting are standard to measure endothelial proliferation. These assays are used to validate hits from screens and to test specific gene functions.
In vivo angiogenesis models
Mouse models of retinal angiogenesis, Matrigel plug assays, and tumor xenografts assess the impact of negative regulators on vascular growth. Endothelial-specific knockout of EPAS1 or RAB3GAP2 has been used to study atherosclerosis and muscle capillarization.
How CRISPR Can Be Used to Study GO:0001937 negative regulation of endothelial cell proliferation
Knockout
CRISPR knockout of candidate negative regulators in endothelial cells can confirm their role in suppressing proliferation. For example, knockout of GNAI2 or NOTCH1 would be expected to increase proliferation, validating their inhibitory function. EDITGENE provides custom knockout cell lines and in vivo models.
Point Mutation
Point mutations can mimic disease-associated variants or alter phosphorylation sites in negative regulators. For instance, mutating specific residues in EPAS1 or GNAI2 may affect their ability to inhibit proliferation. EDITGENE offers precise point mutation knock-in services.
Knock-in
Knock-in of tagged versions (e.g., GFP, HA) allows visualization and biochemical analysis of negative regulators. Tagged NOTCH1 or KLF15 can be used to track localization and interactions. EDITGENE provides tagged knock-in models.
Overexpression
Overexpression of negative regulators such as KLF15, VASN, or microRNAs can suppress endothelial proliferation and angiogenesis. EDITGENE offers lentiviral and CRISPRa overexpression services to study gain-of-function effects.
How EDITGENE Supports negative regulation of endothelial cell proliferation Research
Researchers studying negative regulation of endothelial cell proliferation-related genes often need to determine whether a candidate gene is causally involved in suppressing endothelial cell division. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such functional studies, from knockout to precise point mutations and overexpression.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of endothelial cell proliferation research.
Frequently Asked Questions About negative regulation of endothelial cell proliferation
What is GO:0001937?
GO:0001937 is the Gene Ontology term for negative regulation of endothelial cell proliferation, defined as any process that stops, prevents, or reduces the rate or extent of endothelial cell proliferation.
What genes are involved in negative regulation of endothelial cell proliferation?
Key genes include NOTCH1, KLF15, VASN, EPAS1, GNAI2, RAB3GAP2, and various microRNAs and piRNAs.
How is endothelial cell proliferation negatively regulated?
It is regulated by signaling pathways such as Notch, G protein-coupled receptor signaling, microRNAs, and RNA modifications that suppress pro-proliferative gene expression.
Why is negative regulation of endothelial cell proliferation important in cancer?
Tumors often bypass negative regulation to promote angiogenesis; understanding these mechanisms can lead to anti-angiogenic therapies.
What diseases are associated with dysregulated endothelial cell proliferation?
Cancer, atherosclerosis, and skeletal muscle vascular insufficiency are linked to altered negative regulation.
What experimental models are used to study GO:0001937?
CRISPR knockout, point mutation, knock-in, overexpression in endothelial cells, and in vivo models like retinal angiogenesis and tumor xenografts.
How does Notch signaling negatively regulate endothelial cell proliferation?
Notch1 activation, for example via KLF15/VASN, suppresses pro-proliferative genes and inhibits angiogenesis.
What is the role of EPAS1 in endothelial cell proliferation?
EPAS1 attenuates atherosclerosis initiation at disturbed flow sites by modulating endothelial fatty acid uptake and proliferation.
Can microRNAs negatively regulate endothelial cell proliferation?
Yes, specific microRNAs have been shown to negatively regulate angiogenesis by targeting pro-proliferative factors.
How can CRISPR be used to study negative regulation of endothelial cell proliferation?
CRISPR knockout, activation, or interference screens can identify and validate genes that suppress endothelial proliferation.
Conclusion
GO:0001937, negative regulation of endothelial cell proliferation, is a critical biological process that maintains vascular homeostasis and prevents pathological angiogenesis. Key regulators such as Notch1, KLF15/VASN, EPAS1, GNAI2, and non-coding RNAs have been identified through rigorous research. Understanding these mechanisms offers therapeutic opportunities for cancer, atherosclerosis, and other angiogenesis-dependent diseases. EDITGENE provides comprehensive CRISPR services to accelerate functional studies in this field.
References
- 1. Zhang J et al.. 2025. Endothelial KLF15/VASN Axis Inhibits Angiogenesis via Activation of Notch1 Signaling.. Circ Res 136(12):1595-1609 PMID: 40297901
- 3. Ström K et al.. 2026. RAB3GAP2 is a regulator of skeletal muscle endothelial cell proliferation and associated with capillary-to-fiber ratio.. Cell Rep 45(2):116961 PMID: 41678332
- 4. Bai CW et al.. 2024. G protein subunit alpha i2's pivotal role in angiogenesis.. Theranostics 14(5):2190-2209 PMID: 38505600
- 5. Hirashima M. 2009. Regulation of endothelial cell differentiation and arterial specification by VEGF and Notch signaling.. Anat Sci Int 84(3):95-101 PMID: 19259767
- 6. Sanchez V et al.. 2019. Negative regulation of angiogenesis by novel micro RNAs.. Pharmacol Res 139:173-181 PMID: 30414893
- 7. Pirri D et al.. 2024. EPAS1 Attenuates Atherosclerosis Initiation at Disturbed Flow Sites Through Endothelial Fatty Acid Uptake.. Circ Res 135(8):822-837 PMID: 39234692
- 8. Du SM et al.. 2025. Triple‑negative breast cancer cell‑derived piR‑31115 promotes the proliferation and migration of endothelial cells via METTL3‑mediated m6A modification of YAP1.. Oncol Rep 53(3) PMID: 39820521
